<DOC>
	<DOCNO>NCT00163020</DOCNO>
	<brief_summary>Hypothesis : Among woman twin triplet pregnancy , weekly injection 17-alpha-hydroxyprogesterone caproate ( 17OHP ) , start 24 week gestation , reduce neonatal morbidity reduce rate preterm delivery . This study involve two concurrent double-blinded randomized clinical trial 17OHP versus placebo . Each trial test efficacy safety 17OHP woman specific risk factor preterm birth . The two risk factor study : 1 . Twin pregnancy 2 . Triplet pregnancy</brief_summary>
	<brief_title>17OHP Reduction Neonatal Morbidity Due Preterm Birth ( PTB ) Twin Triplet Pregnancies</brief_title>
	<detailed_description>Prematurity lead cause neonatal morbidity mortality USA . Nationally , 12 % baby deliver term 3 % deliver 32 wks gestational age ( GA ) . Recent study suggest 17OHP progesterone derivative may reduce rate preterm birth among woman history prior preterm birth . However , demonstrate reduction preterm birth accompany clinically significant reduction neonatal complication . Further , woman deliver preterm history prior preterm birth . Little known whether progesterone treatment effective woman risk factor preterm birth multiple gestation . The propose study assess role 17OHP woman twin triplet pregnancy assess impact neonatal health , merely impact gestational age delivery . Prior study design large enough statistical power ass effect neonatal morbidity . In 6 trial combine Goldstein meta-analysis , 279 woman treat 17OHP 73 woman preterm delivery . The NICHD study present Meis approximately double world-wide experience , 306 woman treatment , 73 deliver prior 35 wks . Yet , study design power show reduction neonatal complication reduction preterm birth rate . The present study first specifically design adequate power test whether 17OHP reduces neonatal morbidity among woman one two specific risk factor preterm birth .</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>17-alpha-hydroxy-progesterone caproate</mesh_term>
	<mesh_term>11-hydroxyprogesterone</mesh_term>
	<criteria>1 . Gestational age ( GA ) 1523w0d gestational age time recruitment 2 . GA 16w0dk 23w6d time randomization initiation injection 3 . Maternal age 18 year old 4 . One risk factor spontaneous preterm birth : 1 . Twins current pregnancy , dichorionic placentation 2 . Triplets current pregnancy , trichorionic placentation 5 . Intact membrane 6 . Patient least one detailed 2ndtrimester ultrasound examination document placentation , chorionicity , fetal number , fetal size , amniotic fluid volume , fetal anatomy . ( This examination must comply minimum standard publish American Institute Ultrasound Medicine , American College Radiology , American College Obstetricians &amp; Gynecologists It NOT mandatory examination perform researchstudy center . ) 7 . Investigator believe patient reliable followup visit believe delivery data neonatal data likely available . 1 . Symptomatic uterine contraction current pregnancy 2 . Contraindication intervention intend prolong pregnancy ( include lethal fetal anomaly , amnionitis , preeclampsia , severe oligohydramnios , severe growth delay , fetal death appear imminent inevitable ) 3 . Risk factor major neonatal morbidity unrelated preterm delivery ( monochorionic placentation multiple gestation , major malformation , certain medication exposure ) 4 . Preexisting maternal medical condition might worsen progesterone therapy , include : asthma require medication , renal insufficiency , seizure disorder , ischemic heart disease , active cholecystitis , impair liver function , history thromboembolic disorder , history breast cancer , history major depression require hospitalization . 5 . Preexisting maternal medical condition associate high risk preterm delivery include : refractory hypertension , diabetes nephropathy retinopathy , renal insufficiency , active systemic lupus erythematosus . Note history prior preterm birth NOT exclusion . 6 . Use progesterone progesteronederivative medication 15 week gestation current pregnancy . 7 . Allergy 17OHP oil vehicle . 8 . Placement emergent cerclage ( defined one place occurrence cervical change dilation , funneling , effacement ) pregnancy . Prophylactic cerclage NOT exclusion ( defined one place cervical change , example , history cervical incompetence , prior cervical procedure LEEP cone biopsy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Preterm Birth</keyword>
	<keyword>Preterm Delivery</keyword>
	<keyword>Multiple gestation</keyword>
	<keyword>17-alpha-hydroxyprogesterone caproate</keyword>
	<keyword>Progesterone</keyword>
</DOC>